Trend Report
The Rise of Large-Volume Injectors in a Patient-Centric Era
How large-volume auto-injectors and wearable on-body delivery systems are redefining biologic drug administration — and what it means for the elastomeric components that make them work.
Status
Published
Format
Trend Report
Language
English
Access
Registration Required
Resource Overview
About this White Paper
The pharmaceutical industry's shift toward patient-centric care is accelerating the adoption of large-volume injectors — devices capable of delivering 5 to 20 mL of high-dose or high-viscosity biologics subcutaneously, replacing hours-long intravenous infusions with minutes-long self-injections at home. This 2025 report by Datwyler traces the evolution of the large-volume injectable landscape, from standard 1 mL auto-injectors through today's 5 mL handheld devices and wearable on-body delivery systems (OBDS) for volumes up to 20 mL. It examines the formulation science enabling this shift — including Halozyme's ENHANZE hyaluronidase platform and Elektrofi's Hypercon concentrated microparticle suspension technology — alongside drug container innovation in cyclic olefin polymers (COP/COC) and ultra-thin-wall needle design.
The report provides a pipeline analysis showing that 15% of all biopharmaceuticals in development could qualify as large-volume SC candidates, predominantly monoclonal antibodies targeting oncology, autoimmune, and cardiovascular indications. It then details the elastomeric component requirements specific to large-volume applications — including oily suspension compatibility, complete plunger coating to prevent rubber shedding, consistent glide force across 20 mL formats, and a simplified E&L profile when the same contact material is used for both plunger and combiseal. Datwyler's expanded NeoFlex™ plunger line, engineered for syringes and cartridges up to 20 mL with non-fluorosurfactant fluoropolymer coating, is presented as purpose-built for this growing market segment.
Access This Resource
Download the Trend Report
Continue to access the full resource.
Read the Report
Quick access in under 30 seconds.
